What APC Ltd. does

APC Ltd. is a Dublin-headquartered pharmaceutical process development contract research organization founded in 2011 by CEO Mark Barrett and CTO Brian Glennon out of University College Dublin's School of Chemical and Bioprocess Engineering. The company serves pharmaceutical and biotechnology clients — including eight of the top ten global pharmaceutical companies — with integrated small molecule (synthetic) and large molecule (biologic) process development services across therapeutic areas such as oncology, respiratory disease, Alzheimer's, and HIV. APC operates as part of The Medicine Accelerator group alongside VLE Therapeutics and is fully Irish-owned.

APC's technology stack centers on three proprietary platforms: the ACHIEVE® Platform for synthetic modality development (covering reaction engineering, particle engineering, work-up/distillation, filtration, drying, and formulation), the BioACHIEVE® Platform for biologics (covering microbial, mammalian, viral vectors, cell and gene therapies, and vaccines), and iAchieve®, a cloud-based CMC knowledge management ecosystem that has integrated generative AI and predictive AI capabilities across more than one million digital interactions. The Dublin facility houses 93 Process Analytical Technology tools, continuous processing skids, bioreactors and wave bags, and computational fluid dynamics capability, staffed by approximately 140 PhD scientists.

APC operates a B2B professional services revenue model, with revenue generated through project-based contract research engagements scoped by development phase, complexity, and modality. Go-to-market is direct enterprise sales to pharmaceutical and biotech firms, supplemented by industry-event presence (CPHI Japan, PD2M, Bioprocess International, Bioprocessing Summit), scientific thought leadership, and an inbound inquiry pipeline via the corporate website. In January 2024 the company announced a €100M capital expansion with Enterprise Ireland support to build a 130,000 sq ft Medicine Accelerator Campus in Cherrywood, Dublin — the largest R&D site in Ireland's biopharma sector — targeting combined APC+VLE headcount growth from roughly 270 in 2022 toward 600+ professionals.

Name

APC Ltd.

Legal name

APC Ltd.

Website

https://approcess.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

51–100 employees

Short description

APC Ltd. is a Dublin-based pharmaceutical process development CRO founded in 2011. It serves pharmaceutical and biotech clients — including eight of the top ten global pharma companies — with integrated small molecule and biologics process development across proprietary ACHIEVE®, BioACHIEVE®, and iAchieve® platforms.

Ownership category

akta.pro rank

Product category

Pharmaceutical Process Development Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

akta.pro secondary industries

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Pharmaceutical process development
• Contract research organization
• Biologics manufacturing services
• CMC development platform
• Small molecule synthesis

Headquarters

HQ city

Loughlinstown

HQ country

Ireland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical Process Development Services: APC provides contract research and process development services for pharmaceutical companies across small molecule (synthetics) and large molecule (biologics) modalities. Revenue is generated through project-based engagements delivering process development services across chemistry, crystallization, engineering, analytical, and tech transfer.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels8 records

Core offering

APC Ltd. is a contract research organization that provides pharmaceutical process development services for both small molecule (synthetic) and large molecule (biologics) modalities, helping pharma and biotech clients accelerate the development and launch of medicines. Service offerings span chemistry, crystallization, engineering, analytical, tech transfer, HPAPI handling, upstream and downstream biologics processing, and bioanalytical services, all supported by proprietary ACHIEVE® and BioACHIEVE® platforms, an iAchieve® digital CMC knowledge management ecosystem, and a 93-tool PAT infrastructure.

Product overview

APC Ltd. offers a unified platform-plus-services architecture centered on three core platforms: iAchieve® (cloud-based CMC knowledge management ecosystem), The ACHIEVE® Platform (synthetic modality development), and BioACHIEVE® Platform (biologics development). The company provides comprehensive process development services across both synthetic and biologic modalities, including chemistry, crystallization, engineering, tech transfer, analytical services, and HPAPI handling. A proprietary PAT infrastructure with 93 tools enables real-time monitoring, while AI-enabled analytics within iAchieve® provides predictive and generative AI capabilities for medicine development acceleration. The portfolio spans 134 medicines in process definition, 113 in process development, 57 in process characterization, and 61 in post-launch optimization phases.

Differentiator

Problem solved

Functional benefit

Brands

• iAchieve®: Proprietary cloud-based knowledge management and collaboration ecosystem for CMC that digitizes every aspect of medicine's journey from process definition through process characterization and into manufacturing.
• ACHIEVE® Platform
• BioACHIEVE® Platform

Products and services

• iAchieve® Proprietary cloud-based knowledge management and collaboration ecosystem for Chemistry, Manufacturing, and Controls (CMC) that digitizes every aspect of medicine's journey from process definition through process characterization and into manufacturing. Connects data, quality, and project management systems in a single platform enabling real-time access to project status, data, documentation, and decisions. Sold as part of APC's service engagements to pharma and biotech clients.
• The ACHIEVE® Platform Process development technology platform for synthetic modalities including classic and highly potent synthetic molecules, ADCs, and peptides. Accelerates development and launch through six integrated steps: Reaction Engineering, Crude Particle Engineering, Work Up/Distillation, API Particle Engineering, Filtration & Drying, and Formulation & Tablet Performance. Sold as part of APC's synthetic modality service engagements.
• BioACHIEVE® Platform Process development technology platform for biologics modalities including microbial, mammalian, viral vectors, cell and gene therapies, and vaccines. Spans six integrated steps: Raw Materials & Media, Upstream Processing, Cell Separation, Chromatography, Filtration, and Formulation & Fill Finish. Sold as part of APC's biologics service engagements.
• Chemistry Services Chemical process development services combining deep organic chemistry expertise with process engineering and modeling capabilities. Covers organic synthesis, catalysis, high pressure and low temperature reactions, applicable to both batch and continuous processing modes. For pharma and biotech clients developing synthetic small molecules.
• Crystallization Services Crystallization process design and optimization services addressing nucleation control, particle size distribution, solubility, and supersaturation. Includes in-situ monitoring, population balance modeling, and scale-up strategies. For pharma clients developing solid-form small molecule APIs.
• Engineering Services Scale-up services including computational fluid dynamics, reaction scale-up/scale-down, filtration/washing/drying, and continuous processing for both synthetic and biologic molecules. For pharma and biotech clients needing first-right-time tech transfer into manufacturing.
• HPAPI Services Highly potent active pharmaceutical ingredient development services for ADC and highly potent synthetic programs with best-in-class HPAPI experts and fully equipped development facility. For pharma companies developing ADCs and highly potent compounds.
• Upstream Services Upstream biologics processing services including cell line selection, upstream process design, microcarrier process development, and gene therapy development for transforming yield and productivity. For biopharma clients developing biologics and gene therapies.
• Downstream Services Downstream processing services including chromatography, filtration and separation, and purification optimization for propelling large molecules to patient. For biopharma clients developing large molecule biologics.
• BioAnalytical Services Bioanalytical services serving biologics development programs with comprehensive analytical infrastructure. For biopharma clients needing analytical support across biologics development.
• Cell and Gene Therapies Services Process development services for cell and gene therapies addressing scalability challenges to enable faster delivery of these important therapies to patients. For developers of advanced therapy medicinal products (ATMPs) including viral vectors and cell therapies.

Quantifiable outcome

• 40% reduction in time to manufacture in some cases (2024)
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

Partnerships

Two partnerships are on record, tiered core and major.

• VLE TherapeuticscoreStrategic or Co-development PartnerVLE Therapeutics is part of The Medicine Accelerator group alongside APC. Together they form an Irish Multinational group responsible for breakthrough pharma process research and development (APC) and Manufacture (VLE). The group integrates scientific research, AI, neural networks, and scientifically-led manufacturing activities.
• Bavarian NordicmajorStrategic or Co-development PartnerAPC expanded biologics capabilities to 500L pilot scale with client partner Bavarian Nordic for viral vector product development and manufacture, including MVA-based processes.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Hovione: Hovione is a privately held, mid-sized CDMO specializing in API process development, particle engineering, and GMP manufacturing for small molecules — directly comparable to APC's synthetic modality (ACHIEVE®) platform and HPAPI capabilities. Both are science-led, founder-influenced CROs serving top global pharma.
• Cambrex: Cambrex is a small-molecule API and finished dosage CDMO with deep process development and scale-up expertise. Comparable to APC's synthetic process development, crystallization, and tech transfer offerings across the small-molecule value chain.
• AGC Biologics: AGC Biologics is a mid-to-large CDMO providing process development, scale-up, and GMP manufacturing for mammalian, microbial, and cell & gene therapy biologics. Closely comparable to APC's biologics process development and viral vector capabilities (e.g., Bavarian Nordic–type engagements).

Broad incumbents

• Lonza Group: Lonza is a global, large-cap CDMO with end-to-end small- and large-molecule development through commercial manufacturing. Comparable to APC across both modalities but at vastly greater scale and with integrated commercial capacity APC does not directly offer.
• Catalent: Catalent is a global CDMO providing development, delivery, and manufacturing solutions across biologics, cell & gene therapies, and oral dose forms. Comparable in modality breadth to APC's BioACHIEVE® plus cell & gene therapy offerings, with substantially larger scale.
• Samsung Biologics: Samsung Biologics is a large-scale biologics CDMO offering process development through commercial manufacturing. Comparable to APC's BioACHIEVE® offerings in upstream/downstream biologics development, with much larger commercial-scale capacity.
• WuXi STA (WuXi AppTec): WuXi STA is a global CDMO providing small-molecule API development and manufacturing plus biologics services. Comparable to APC's dual-modality platform but at a much larger scale and with integrated commercial manufacturing.
• Thermo Fisher Scientific (Patheon CDMO): Thermo Fisher's Patheon CDMO business offers end-to-end pharmaceutical development and manufacturing services across small and large molecules. Comparable across the full development-to-commercial continuum that APC addresses only on the development side.
• Charles River Laboratories: Charles River is a global CRO/CDMO with biologics process development and manufacturing services. Comparable to APC's BioACHIEVE® offerings and broader contract research portfolio, with substantially larger scale and a broader service menu.
• Recipharm: Recipharm is a European-headquartered CDMO offering small-molecule development, manufacturing, and biologics services. Comparable in European footprint and small-molecule process development orientation, with broader commercial manufacturing capacity.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/apcinnovate
• YouTubeyoutube.com/channel/UCQkQxcXKkk5gYgZcBhCn_Ig
• LinkedInlinkedin.com/company/the-applied-process-company

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about APC Ltd.